Evidence map›Paper›PMID 38698669›Full record

ArticleTransplant infectious disease : an official journal of the Transplantation Society2024

Influence of induction therapy and antiretroviral regimen on outcomes in kidney transplant recipients living with human immunodeficiency.

Christin Rogers Marks, Christine M Durand, Mary G Bowring, Jonathan Hand, Maheen Z Abidi, Maricar Malinis, Brittany Barnaba, Het Patel, Martha Pavlakis, Carolyn D Alonso

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Transplant infectious disease : an official journal of the Transplantation Society, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Christin Rogers MarksDivision of Infectious Disease, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.ORCID https://orcid.org/0000-0002-0783-6535
Christine M DurandJohns Hopkins Medical Center, Baltimore, Maryland, USA.
Mary G BowringJohns Hopkins Medical Center, Baltimore, Maryland, USA.
Jonathan HandOchsner Health, New Orleans, Louisiana, USA.
Maheen Z AbidiDivision of Infectious Disease, University of Colorado Anschutz Medical Center, Aurora, Colorado, USA.
Maricar MalinisYale New Haven Hospital, New Haven, Connecticut, USA.ORCID https://orcid.org/0000-0002-5720-9994
Brittany BarnabaJohns Hopkins Medical Center, Baltimore, Maryland, USA.
Het PatelDivision of Nephrology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
Martha PavlakisDivision of Nephrology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
Carolyn D AlonsoDivision of Infectious Disease, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.ORCID https://orcid.org/0000-0002-3140-1128

Funding

CMV and CMV-Immune Responses in Geriatric Conditions Post-Kidney Transplant (CMV-GeriKT)K23AG073534 · NIA · UNIVERSITY OF COLORADO DENVER · PI ABIDI, MAHEEN ZEHRA · 2021 to 2025
$944k
Leveraging a novel health records platform to predict the development of cardiovascular disease following kidney transplantationF30HL168842 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI BOWRING, MARY GRACE · 2023 to 2025
$170k
National Institute of Aging 1K23AG073534-01National Institute of Aging NHLBI F30HL168842NHLBI NIH HHS F30 HL168842NIA NIH HHS K23 AG073534
6 · The paper itself

Abstract

purposeKidney transplantation has a survival benefit for people with human immunodeficiency virus (HIV) and end-stage kidney disease, however increased rates of rejection remain an issue. Questions remain regarding the impact of induction immunosuppression therapy and antiretroviral (ARV) choice on long-term outcomes.

methodsWe performed a multicenter retrospective analysis of outcomes in recipients with HIV who received kidneys from donors without HIV transplanted between 2004 and 2019. The association between induction and ARV regimens and long-term outcomes including rejection, graft, and recipient survival over 5 years was investigated using Cox regression modeling.

resultsSeventy-eight kidney transplants (KT) performed in 77 recipients at five US transplant centers were included, with median follow up of 7.1 (4.3-10.7) years. Overall recipient and graft survival were 83% and 67%, respectively. Rejection occurred in 37% (29/78). Recipients with rejection were more likely to be younger, recipients of deceased donor organs, and Black. Receipt of rabbit anti-thymocyte globulin (rATG) induction without protease-inhibitor (PI)-based ARVs was associated with 83% lower risk of rejection (adjusted hazard ratio (aHR) 0.17 (95% CI 0.05-0.63), p =.007) and a non-statistically significantly lower risk of graft failure (aHR 0.18 (0.03-1.16), p =.07) when compared to those who received other induction and ARV combinations.

conclusionsIn this multicenter retrospective study, we found a trend toward lower rejection and improved graft survival among those who received both rATG for induction and PI-sparing ARVs.

Indexed as

Antilymphocyte SerumGraft RejectionGraft SurvivalHIV InfectionsKidney TransplantationAdultAnti-Retroviral AgentsFemaleHumansImmunosuppression TherapyImmunosuppressive AgentsInduction ChemotherapyKidney Failure, ChronicMaleMiddle AgedRetrospective StudiesAntilymphocyte SerumAnti-Retroviral AgentsImmunosuppressive Agentshuman immunodeficiency virusrejectiontransplantation

Identifiers

PMID38698669
PMCPMC12498429

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.